Gilles Wandeler1, Thomas Gsponer, Lloyd Mulenga, Daniela Garone, Robin Wood, Mhairi Maskew, Hans Prozesky, Christopher Hoffmann, Jochen Ehmer, Diana Dickinson, Mary-Ann Davies, Matthias Egger, Olivia Keiser. 1. aDivision of International and Environmental Health, Institute of Social and Preventive Medicine (ISPM), University of Bern bDepartment of Infectious Diseases, University Hospital Bern, Bern, Switzerland cCentre for Infectious Disease Research in Zambia, Lusaka, Zambia dKhayelitsha ART Programme, Médecins Sans Frontières, Cape Town eThe Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town fThemba Lethu Clinic, Johannesburg gDivision of Infectious Diseases, Department of Medicine, University of Stellenbosch and Tygerberg Academic Hospital, Cape Town hAurum Institute for Health Research, Johannesburg, South Africa iSolidarMed Lesotho, Lucerne, Switzerland jHIV private practice, Gaborone, Botswana kSchool of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Abstract
OBJECTIVES: Zidovudine (ZDV) is recommended for first-line antiretroviral therapy (ART) in resource-limited settings. ZDV may, however, lead to anemia and impaired immunological response. We compared CD4+ cell counts over 5 years between patients starting ART with and without ZDV in southern Africa. DESIGN: Cohort study. METHODS: Patients aged at least 16 years who started first-line ART in South Africa, Botswana, Zambia, or Lesotho were included. We used linear mixed-effect models to compare CD4+ cell count trajectories between patients on ZDV-containing regimens and patients on other regimens, censoring follow-up at first treatment change. Impaired immunological recovery, defined as a CD4+ cell count below 100 cells/μl at 1 year, was assessed in logistic regression. Analyses were adjusted for baseline CD4+ cell count and hemoglobin level, age, sex, type of regimen, viral load monitoring, and calendar year. RESULTS: A total of 72,597 patients starting ART, including 19,758 (27.2%) on ZDV, were analyzed. Patients on ZDV had higher CD4+ cell counts (150 vs.128 cells/μl) and hemoglobin level (12.0 vs. 11.0 g/dl) at baseline, and were less likely to be women than those on other regimens. Adjusted differences in CD4+ cell counts between regimens containing and not containing ZDV were -16 cells/μl [95% confidence interval (CI) -18 to -14] at 1 year and -56 cells/μl (95% CI -59 to -52) at 5 years. Impaired immunological recovery was more likely with ZDV compared to other regimens (odds ratio 1.40, 95% CI 1.22-1.61). CONCLUSION: In southern Africa, ZDV is associated with inferior immunological recovery compared to other backbones. Replacing ZDV with another nucleoside reverse transcriptase inhibitor could avoid unnecessary switches to second-line ART.
OBJECTIVES:Zidovudine (ZDV) is recommended for first-line antiretroviral therapy (ART) in resource-limited settings. ZDV may, however, lead to anemia and impaired immunological response. We compared CD4+ cell counts over 5 years between patients starting ART with and without ZDV in southern Africa. DESIGN: Cohort study. METHODS:Patients aged at least 16 years who started first-line ART in South Africa, Botswana, Zambia, or Lesotho were included. We used linear mixed-effect models to compare CD4+ cell count trajectories between patients on ZDV-containing regimens and patients on other regimens, censoring follow-up at first treatment change. Impaired immunological recovery, defined as a CD4+ cell count below 100 cells/μl at 1 year, was assessed in logistic regression. Analyses were adjusted for baseline CD4+ cell count and hemoglobin level, age, sex, type of regimen, viral load monitoring, and calendar year. RESULTS: A total of 72,597 patients starting ART, including 19,758 (27.2%) on ZDV, were analyzed. Patients on ZDV had higher CD4+ cell counts (150 vs.128 cells/μl) and hemoglobin level (12.0 vs. 11.0 g/dl) at baseline, and were less likely to be women than those on other regimens. Adjusted differences in CD4+ cell counts between regimens containing and not containing ZDV were -16 cells/μl [95% confidence interval (CI) -18 to -14] at 1 year and -56 cells/μl (95% CI -59 to -52) at 5 years. Impaired immunological recovery was more likely with ZDV compared to other regimens (odds ratio 1.40, 95% CI 1.22-1.61). CONCLUSION: In southern Africa, ZDV is associated with inferior immunological recovery compared to other backbones. Replacing ZDV with another nucleoside reverse transcriptase inhibitor could avoid unnecessary switches to second-line ART.
Authors: Matthias Egger; Didier K Ekouevi; Carolyn Williams; Rita Elias Lyamuya; Henri Mukumbi; Paula Braitstein; Tyler Hartwell; Claire Graber; Benjamin H Chi; Andrew Boulle; François Dabis; Kara Wools-Kaloustian Journal: Int J Epidemiol Date: 2011-05-18 Impact factor: 7.196
Authors: A Zoufaly; M an der Heiden; C Kollan; J R Bogner; G Fätkenheuer; J C Wasmuth; M Stoll; O Hamouda; J van Lunzen Journal: J Infect Dis Date: 2010-12-08 Impact factor: 5.226
Authors: J J Eron; R L Murphy; D Peterson; J Pottage; D M Parenti; J Jemsek; S Swindells; G Sepulveda; N Bellos; B C Rashbaum; J Esinhart; N Schoellkopf; R Grosso; M Stevens Journal: AIDS Date: 2000-07-28 Impact factor: 4.177
Authors: Hermann Bussmann; C William Wester; Ann Thomas; Vladimir Novitsky; Reginald Okezie; Tanaka Muzenda; Tendani Gaolathe; Ndwapi Ndwapi; Norah Mawoko; Erik Widenfelt; Sikhulile Moyo; Rosemary Musonda; Madisa Mine; Joseph Makhema; Howard Moffat; Max Essex; Victor Degruttola; Richard G Marlink Journal: J Acquir Immune Defic Syndr Date: 2009-05-01 Impact factor: 3.731
Authors: Christian Laurent; Anke Bourgeois; Eitel Mpoudi-Ngolé; Laura Ciaffi; Charles Kouanfack; Rose Mougnutou; Nathalie Nkoué; Alexandra Calmy; Sinata Koulla-Shiro; Eric Delaporte Journal: AIDS Res Hum Retroviruses Date: 2008-03 Impact factor: 2.205
Authors: Jialun Zhou; Antoine Jaquet; Emmanuel Bissagnene; Beverly Musick; Kara Wools-Kaloustian; Nicola Maxwell; Andrew Boulle; Firas Wehbe; Daniel Masys; Jeniffer Iriondo-Perez; Jay Hemingway-Foday; Matthew Law Journal: J Int AIDS Soc Date: 2012-01-30 Impact factor: 5.396
Authors: Felix R Kayigamba; Molly F Franke; Mirjam I Bakker; Carly A Rodriguez; Emmanuel Bagiruwigize; Ferdinand Wnm Wit; Michael L Rich; Maarten F Schim van der Loeff Journal: PLoS One Date: 2016-07-20 Impact factor: 3.240
Authors: Fiona Vanobberghen; Emilio Letang; Anna Gamell; Dorcas K Mnzava; Diana Faini; Lameck B Luwanda; Herry Mapesi; Kim Mwamelo; George Sikalengo; Marcel Tanner; Christoph Hatz; Hansjakob Furrer; Manuel Battegay; Tracy R Glass Journal: PLoS One Date: 2017-07-18 Impact factor: 3.240